https://www.grunenthal.com/en/press-room/press-releases/2019/pr-gruenenthal-mesoblast-enter-strategic-partnership-innovative-cell-therapy-chronic-low-back-pain#:~:text=Under%20the%20partnership%2C%20Gr%C3%BCnenthal%20will,as%20further%20commercialisation%20milestone%20payments.
Is the confirmatory Ph III CLBP trial going to include European sites? I can’t recall seeing anything mentioned by the company (but vaguely remember, perhaps from way back, that the confirmatory might have European involvement), but they could receive a milestone payment from Grunenthal on the commencement of such, according to this. I’m not sure if this is the original announcement or the latest, post re-negotiation.
Does anyone know? Is it not a priority atm?
banter and General Discussion, page-10005
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.020(2.02%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.01 | 94.3¢ | $4.168M | 4.312M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 118044 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 61687 | 9 |
View Market Depth
| Last trade - 13.55pm 01/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |